CNCR vs. XMMO

Last updated Jun 3, 2026

CNCR (Loncar Cancer Immunotherapy ETF) and XMMO (Invesco S&P MidCap Momentum ETF) are both exchange-traded funds - CNCR is a Health & Biotech Equities fund tracking the Loncar Cancer Immunotherapy Index, while XMMO is a Momentum fund tracking the S&P MidCap 400 Momentum Index. Both are passively managed. CNCR charges 0.79%/yr vs 0.35%/yr for XMMO.

Performance

CNCR vs. XMMO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Loncar Cancer Immunotherapy ETF (CNCR) and Invesco S&P MidCap Momentum ETF (XMMO). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

CNCR

• 1D: 0.00%
• 1M: 0.00%
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

XMMO

• 1D: 2.16%
• 1M: 6.07%
• YTD: 22.96%
• 6M: 24.84%
• 1Y: 37.37%
• 3Y*: 31.83%
• 5Y*: 16.81%
• 10Y*: 19.66%

*Multi-year figures are annualized to reflect compound growth (CAGR)

CNCR vs. XMMO - Yearly Performance Comparison

	2026 (YTD)
CNCR Loncar Cancer Immunotherapy ETF	0.00%
XMMO Invesco S&P MidCap Momentum ETF	16.10%

CNCR vs. XMMO - Sectors Allocation Comparison

Sectors	CNCR	XMMO
Healthcare	96.6%	6.3%
Financial Services	3.3%	2.4%
Basic Materials	-	7.2%
Communication Services	-	1.6%
Consumer Cyclical	-	4.6%
Consumer Defensive	-	0.5%
Energy	-	7.7%
Industrials	-	41.1%
Real Estate	-	6.1%
Technology	-	16.7%
Utilities	-	5.8%

Return for Risk

CNCR vs. XMMO — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

XMMO

XMMO Risk / Return Rank: 69
XMMO Sharpe Ratio Rank: 59
XMMO Sortino Ratio Rank: 59
XMMO Omega Ratio Rank: 56
XMMO Calmar Ratio Rank: 84
XMMO Martin Ratio Rank: 86

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CNCR vs. XMMO - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Loncar Cancer Immunotherapy ETF (CNCR) and Invesco S&P MidCap Momentum ETF (XMMO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

Sharpe Ratios by Period

	CNCR	XMMO	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	—	2.01	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	0.79	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.89	—
Sharpe Ratio (All Time) Calculated using the full available price history	—	0.57	—

Drawdowns

CNCR vs. XMMO - Drawdown Comparison

The maximum CNCR drawdown since its inception was 0.00%, smaller than the maximum XMMO drawdown of -55.37%. Use the drawdown chart below to compare losses from any high point for CNCR and XMMO.

Drawdown Indicators

	CNCR	XMMO	Difference
Max Drawdown Largest peak-to-trough decline	0.00%	-55.37%	+55.37%
Max Drawdown (1Y) Largest decline over 1 year	—	-8.34%	—
Max Drawdown (3Y) Largest decline over 3 years	—	-24.93%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-27.91%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-36.74%	—
Current Drawdown Current decline from peak	0.00%	0.00%	0.00%
Average Drawdown Average peak-to-trough decline	0.00%	-9.45%	+9.45%
Ulcer Index Depth and duration of drawdowns from previous peaks	—	2.04%	—

Volatility

Volatility by Period

	CNCR	XMMO	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	7.82%	—
Volatility (6M) Calculated over the trailing 6-month period	—	15.59%	—
Volatility (1Y) Calculated over the trailing 1-year period	0.00%	18.71%	-18.71%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	0.00%	21.45%	-21.45%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	0.00%	22.27%	-22.27%

CNCR vs. XMMO - Expense Ratio Comparison

CNCR has a 0.79% expense ratio, which is higher than XMMO's 0.35% expense ratio.

Dividends

CNCR vs. XMMO - Dividend Comparison

CNCR has not paid dividends to shareholders, while XMMO's dividend yield for the trailing twelve months is around 0.61%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
CNCR Loncar Cancer Immunotherapy ETF	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
XMMO Invesco S&P MidCap Momentum ETF	0.61%	0.78%	0.34%	0.80%	1.43%	0.41%	0.61%	0.60%	0.19%	0.21%	0.22%	0.64%

Frequently Asked Questions

Which ETF is better, CNCR or XMMO?

On fees, XMMO is cheaper at 0.35% per year. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF is cheaper, CNCR or XMMO?

XMMO is cheaper with a 0.35% expense ratio, compared with 0.79% for CNCR.

Which ETF pays a higher dividend yield, CNCR or XMMO?

XMMO has the higher dividend yield at 0.61%, compared with 0.00% for CNCR.

What is the main difference between CNCR and XMMO?

CNCR is categorized as Health & Biotech Equities, while XMMO is Momentum. CNCR tracks Loncar Cancer Immunotherapy Index, while XMMO tracks S&P MidCap 400 Momentum Index. They also come from different issuers: Exchange Traded Concepts and Invesco. Their fees differ too: 0.79% for CNCR and 0.35% for XMMO.